The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, said on 23 February 2021 that Mexico, the first country in North America to approve Russia's Sputnik V COVID-19 vaccine, has received its first batch of the vaccine, CNN reported on Tuesday.
In a statement, the RDIF said: "On 3 February 2021, the Federal Commission for the Protection against Sanitary Risk of Mexico (COFEPRIS) approved Sputnik V under the emergency use authorisation procedure without additional clinical trials in the country."
Kirill Dmitriev, CEO of the RDIF, said: "it is a significant breakthrough in Russia's efforts to fight COVID-19 and clearly shows that saving lives is above politics."
According to figures from the RDIF, which oversees global distribution and sales of the vaccine, Russia's Sputnik V COVID-19 vaccine has now been approved for use in more than 30 countries and is one of the world's most pre-ordered vaccines, with at least 50 countries, from Argentina to the Philippines, ordering nearly 2.5 billion doses so far.
A tally by Johns Hopkins University has revealed that Mexico has the third highest death toll in the world, behind the US and Brazil, with more than 180,000 deaths.
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results